FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas

The product is the first and only CD19-targeted antibody drug conjugate (ADC) available for this disease, and was granted an accelerated approval based on overall response rate.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news